Most Popular

1
Education Cannot Wait Announces US$20 Million Multi-Year-Resilience Programme Catalytic Grant in Chad, Total ECW Funding in Chad Tops US$61 Million

NewsletterSubscribe

Start your day with a roundup of key stories from The Korea Herald with news and comment on all that’s happening in Korea.

Boryung Pharma to commercialize Aplidin from Spain

By 윤정현

Published : Oct. 4, 2016 - 14:14

- Link copied

[DISCLOSURE] Boryung Pharmaceutical (003850) reported on Oct. 4 that it has signed a technology introduction contract with PharmaMar of Spain for rights to launch and commercialize Aplidin, a treatment option for multiple myeloma, in Korea.

By Yun Jeong-hyeon (clareyun@heraldcorp.com)

Boryung Pharma to commercialize Aplidin from Spain

More from Headlines